

Safety: Two patients (5.1%) had procedural safety events: 1 thrombus with minor thalamic infarct, mRS 1 at discharge and 1 microguidewire trauma leading to SAH. One patient (5%) required repeat coiling. No subsequent safety events occurred through follow-up.

Conclusion eCLIPS has an effective flowdiversion effect, and it enables durable coilsupport.

Aneurysm occlusion grade remained unchanged or better at all follow-up timepoints.

eCLIPS has a satisfactory safety profile.

Disclosure of Interest no.

1.2. Brain AVM/AVF, spinal vascular malformations

P097 PRELIMINARY EXPERIENCE WITH IHTOBTURA®: A NOVEL NON-ADHESIVE LIQUID EMBOLIC AGENT, WITH POST EMBOLIZATION LOSS OF RADIOCAPACITY, FOR THE ENDOVASCULAR TREATMENT OF BRAIN ARTERIOVENOUS MALFORMATIONS. CLARIDAD STUDY

Juan Carlos Llibre Guerra. Hospital Universitario de Salamanca, Instituto de neurología y Neurocirugía. La Habana. Cuba, Spain

10.1136/jnis-2024-ESMINT.133

Introduction ihtOBTURA® (IBERHOSPITEX, Llica de Ball, Spain) is a revolutionary non-adhesive liquid embolic agent, composed by EVOH copolymer and an iodinated compound, dissolved in DMSO

Aim of Study To report a Preliminary Experience with ihtOBTURA®: A Novel Non-Adhesive Liquid Embolic Agent, with post embolization loss of radiopacity, for the Endovascular Treatment of Brain Arteriovenous Malformations

Methods We performed a prospective longitudinal single center study, from November 10, 2021, to September 10, 2022. 42 consecutive patients with brain AVMs, were treated by

endovascular way. A total of 102 endovascular procedures were performed with ihtOBTURA®. There were 23 males and 19 females with a mean age of 37.38 years. The most common clinical presentation was intracranial hemorrhage in 35 (83.33%) patients. According to the Spetzler-Martin scale, 25 (59,52%) AVMs were grades IV; 13 (30,95%) AVMs, grade III; and 4 (9,52) AVMs, grades II

Results Complete occlusion was achieved in 26/28 patients (93%) during the study interval, and in 61.90% (26/42) in the entire patient cohort. The 14 remaining patients are scheduled for further EVT. Stability of angiographic occlusion was confirmed in all 26 patients by a control angiogram at 6 months. Mean volume reduction was 80,79% per patients. whereas an average of 7.2 mL of ihtOBTURA® was used per patient. Disabling Permanent Neurological Deficits included 1 case of postinterventional hemorrhage and there were 1 procedure-related death.

Conclusion ihtOBTURA® is a safe and effective new non-adhesive liquid embolic agent, with innovative properties that can improve results on AVMs treatment.

Disclosure of Interest no.


1.3 Miscellaneous

P098 PRESERVATION OF RADIOCAPACITY IN ETHYLENE-VINYL ALCOHOL LIQUID EMBOLIZATION AGENTS THROUGH MANUAL AGITATION: A COMPREHENSIVE MULTIPARAMETRIC IN-VITRO STUDY

^{1,2}Thibault Agripnidis, ^{1,2}Jean-François Hak, ¹Jan-Patrick Stellmann. ¹AP HM, Timone Hospital, Neuroradiology, ²Laboratoire d'Imagerie Interventionnelle Expérimentale (LiE), CERIMED

10.1136/jnis-2024-ESMINT.134

Introduction The formation of a solid plug using Ethylene-Vinyl Alcohol liquid embolization agents (EVOH LEAs) is a



Abstract P098 Figure 1 Boxplot displaying the visibility scale (ordinate) identified blind by 2 EVOH LEA neuroradiologists within 1mL syringes with variable waiting times of 3 minutes, 5 minutes, 7 minutes and 10 minutes (abscissa) depending on the type of shaking method used (either manual or automatic, and either rotational or horizontal)